Phospho-ATF-2 (Thr71)/ATF-7 (Thr53) (A8J7P) Rabbit mAb #15411
- WB
- F
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 65,75 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- F-Flow Cytometry
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Flow Cytometry (Fixed/Permeabilized) | 1:1600 |
Storage
For a carrier free (BSA and azide free) version of this product see product #46615.
Protocol
Specificity / Sensitivity
Phospho-ATF-2 (Thr71)/ATF-7 (Thr53) (A8J7P) Rabbit mAb detects endogenous levels of ATF-2 and ATF-7 only when phosphorylated at threonine 71 and threonine 53, respectively. This antibody does not cross-react with phosphorylated c-Jun, CREB, or other transcription factors. It recognizes Thr69/Thr71 dually phosphorylated ATF-2, Thr51/Thr53 dually phosphorylated ATF-7, Thr71 singly phosphorylated ATF-2, and Thr53 singly phosphorylated ATF-7 equally well.
Species Reactivity:
Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Thr71 of human ATF-2 protein.
Background
The transcription factor ATF-2 (also called CRE-BP1) binds to both AP-1 and CRE DNA response elements and is a member of the ATF/CREB family of leucine zipper proteins (1). ATF-2 interacts with a variety of viral oncoproteins and cellular tumor suppressors and is a target of the SAPK/JNK and p38 MAP kinase signaling pathways (2-4). Various forms of cellular stress, including genotoxic agents, inflammatory cytokines, and UV irradiation, stimulate the transcriptional activity of ATF-2. Cellular stress activates ATF-2 by phosphorylation of Thr69 and Thr71 (2-4). Both SAPK and p38 MAPK have been shown to phosphorylate ATF-2 at these sites in vitro and in cells transfected with ATF-2. Mutations of these sites result in the loss of stress-induced transcription by ATF-2 (2-4). In addition, mutations at these sites reduce the ability of E1A and Rb to stimulate gene expression via ATF-2 (2).
ATF-7 is another member of the ATF/CREB family of leucine zipper proteins (5). Similarly, Thr51 and Thr53 (corresponding to Thr69 and Thr71 of ATF-2, respectively) can be phosphorylated under different conditions (6,7).
- Abdel-Hafiz, H.A. et al. (1992) Mol Endocrinol 6, 2079-89.
- Gupta, S. et al. (1995) Science 267, 389-93.
- van Dam, H. et al. (1995) EMBO J 14, 1798-811.
- Livingstone, C. et al. (1995) EMBO J 14, 1785-97.
- Peters, C.S. et al. (2001) J Biol Chem 276, 13718-26.
- Camuzeaux, B. et al. (2008) J Mol Biol 384, 980-91.
- Maekawa, T. et al. (2010) EMBO J 29, 196-208.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.